MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Medical Tourism
Compare and save on surgery

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
headlines news headlines   email email to a friend   printer printer friendly   newsletter sign up to newsletter  

Pro-vitamin E Shown To Be Active Against Breast Cancer Cells

Main Category: Breast Cancer
Also Included In: Conferences | Colorectal Cancer | Asbestos / Mesothelioma
Article Date: 14 Dec 2006

A precursor of vitamin E has been shown to be effective against breast cancer cell lines which over-express human epidermal growth factor receptor (HER2).

About 30% of breast cancers exhibit high levels of HER2 - a feature that appears to make the disease resistant to many common treatments including chemotherapeutic agents.

Now researchers in Griffith University's School of Medical Science have shown that pro-vitamin E or alpha-tocopheryl succinate can reduce tumour volume in experimental animals with high levels of HER2.

Chief investigator Associate Professor Jiri Neuzil said alpha-tocopheryl succinate (alpha-TOS) had the potential to be an inexpensive, safe and selective therapy for hard-to-treat breast cancers.

"Alpha-TOS has already shown promise as a potent anticancer agent in diseases such as colon cancer and mesothelioma. It induces controlled cell death or apoptosis in tumour cells."

Transgenic mice with high HER2 breast cancers were treated over a three week period and tumour size was monitored every three days by ultrasound imaging.

The high resolution ultrasound allows for more accurate measurement of tumour volume than any other non-invasive technique.

The research team found that while alpha-TOS is effective alone, it can be delivered into the tumour cells more efficiently when given in a conjugate form with a targeting peptide.

"Tumour volume reduced more than 50% when animals were treated with the conjugate rather than free alpha-TOS," Associate Professor Neuzil said.

He said one of the benefits of alpha-TOS as a potential anti-cancer drug was that it was metabolised in the liver to vitamin E and unlikely to cause dangerous side effects.

Associate Professor Neuzil is presenting his results at the Gold Coast Health and Medical Research Conference. The conference, an initiative of the Griffith Institute of Health and Medical Research, is being held December 14-15, at the Radisson Palm Meadows Resort, Gold Coast.

###

Contact: Mardi Chapman
Research Australia

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.





For any corrections of factual information, or to contact the editors please use our feedback form.
Send your press releases to








free web search box


pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.